Posted by Michael Wonder on 28 Dec 2023
Application for COVID-19 vaccine Nuvaxovid against Omicron variant XBB.1.5 withdrawn
18 December 2023 - The manufacturer Novavax is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland.
Future Health Pharma GmbH has announced on behalf of the manufacturer Novavax that it will not be pursuing the change of marketing authorisation for its COVID-19 vaccine adapted against Omicron sub-variant XBB.1.5. The pharmaceutical company has withdrawn the application for authorisation of the protein-based vaccine Nuvaxovid submitted to Swissmedic on 30 August 2023.
